83889-95-6

Usage

Furan-2,3-dione derivative

A chemical structure based on a furan ring (a five-membered ring with one oxygen atom and four carbon atoms) with two carbonyl groups (C=O) at the 2nd and 3rd positions.

Naphtho[2,3-b]furan ring system

A fused ring structure consisting of a naphthalene (a ten-carbon aromatic ring system) and a furan ring sharing two adjacent carbon atoms at positions 2 and 3.

Hydroxyethyl group

A functional group containing an oxygen atom bonded to a carbon atom, which is in turn bonded to two hydrogen atoms and an ethyl group (-CH2-CH3).

Attached at the 2-position

The hydroxyethyl group is attached to the second carbon atom of the naphtho[2,3-b]furan ring system.

Potential biological activities

The compound's structural features may lead to interactions with biological systems, making it a candidate for further study in the field of medicinal chemistry.

Applications in medicinal chemistry

Due to its potential biological activities, the compound may be useful in the development of new drugs or therapies.

Interesting for further study

The compound's unique structure and potential applications make it a valuable subject for research in various scientific and industrial fields.

Upstream product

• 2028-63-9 but-3-yn-2-ol 
• 83-72-7 2-hydroxynaphtho-1,4-quinone 
• 124575-68-4 2-ethylnaphtho[1,2-b]furan-4,5-dione 
• 18633-71-1 2-ethyl-4H,9H-naphtho[2,3-b]furan-4,9-dione 
• 85-44-9 phthalic anhydride 
• 57901-54-9 2-(2-furoyl)benzoic acid 
• 91394-68-2 2-bromo-3-(dimethylamino)naphthalene-1,4-dione 
• 2065-37-4 2-bromo-1,4-naphthoquinone 
• 2348-79-0 2-dimethylamino-1,4-naphthoquinone 
• 117560-06-2 3-phenyliodonio-1,2,4-trioxo-1,2,3,4-tetrahydronaphthalenide 
• 1785-67-7 1,2,4-triacetyloxynaphthalene 
• 130-15-4 [1,4]naphthoquinone 
• 1203-39-0 3-bromolawsone 
• 29366-43-6 2-hydroxy-3-(1-n-butenyl)-1,4-naphthoquinone 

Downstream Products

• 83280-65-3 2-acetylnaphtho[2,3-b]furan-4,9-quinone 

Relevant academic research and scientific papers

Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer

Increasing evidence indicates that the cancer stem cell (CSC) subpopulation contributes to the therapeutic resistance and metastasis of tumors, leading to patient recurrence and death. Herein, we designed and synthesized several compounds by conjugating lapatinib derivatives with different CSC inhibitors to treat with lapatinib-induced MDA-MB-231 drug-resistant cells. In vitro biological studies indicated that 3a showed strong cytotoxicity and EGFR enzyme inhibitory activity and effectively reversed lapatinib-mediated resistance of MDA-MB-231 cells via inhibiting triple-negative breast cancer (TNBC) cell stemness and the AKT/ERK signaling pathway. In addition, 3a was capable of strongly suppressing the invasion and migration of TNBC cells by inhibiting the Wnt/β-catenin signaling pathway and MMP-2 and MMP-9 protein expression. In vivo tumorigenicity tests showed that 3a could inhibit the occurrence of TNBC by inhibiting BCSCs, proving 3a is a potential EGFR and CSC dual inhibitor for TNBC treatment.

Novel small molecule compound, preparation method and application thereof in preparation of mycobacterium drugs for resisting drug-resistant mycobacterium tuberculosis and like

The invention discloses a novel small molecule compound and a preparation method and application thereof in preparation of mycobacterium drugs for resisting drug-resistant mycobacterium tuberculosis and like. The novel mycobacterium-resistant small molecule has a structural general formula (I), and the small molecule compound disclosed by the invention has a relatively good inhibition effect on mycobacteria. The antibacterial activity of mycobacterium smegmatis, mycobacterium tuberculosis H37Rv, H37Ra and drug-resistant mycobacterium tuberculosis are determined, and results show that the smallmolecule compound has good antibacterial activity on mycobacterium smegmatis, mycobacterium tuberculosis H37Rv, H37Ra and drug-resistant mycobacterium tuberculosis, and has an application prospect inpreparation of mycobacterium tuberculosis-resistant drugs.

Discovery of napabucasin derivatives for the treatment of tuberculosis

Tuberculosis is the contagious disease responsible for the highest number of deaths worldwide. Here, we screened a commercially available compound library and found napabucasin to possess a moderate anti-tubercular activity against M. tuberculosis H37Ra (MIC 2.5 μg mL-1, 10.4 μM). Three series of napabucasin derivatives were further evaluated for their in vitro anti-tubercular activities against Mtb H37Ra. The activity of most derivatives was either retained or enhanced compared with that of napabucasin. Compound 3s was the most active compound showing a MIC value of 0.3125 μg mL-1 (0.9 μM). Furthermore, several compounds were selected and evaluated against the Mtb H37Rv standard strain and six Mtb clinical isolates. Importantly, these compounds were found to be effective against Mtb clinical isolates with multi-resistance to isoniazid, rifampicin, and ethambutol.

METHOD FOR PRODUCING 2-ALKYLCARBONYLNAPHTHO[2,3-b]FURAN-4,9-DIONE-RELATED SUBSTANCE, AND SAID RELATED SUBSTANCE

Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of

Design, synthesis and activity of BBI608 derivatives targeting on stem cells

STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells. BBI608, a small molecule identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types. In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivatives were designed and synthesized here. Most of these compounds were more potent than BBI608 on HepG2 cells, compound LD-8 had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50 = 11.2 μM), but had considerable activity on normal liver cells L-02. Compounds LD-17 (IC50 = 3.5 μM) and LD-19 (IC50 = 2.9 μM) were found to possess significant inhibitory activities and good selectivity. The results showed that compound LD-19 was worthy to investigate further as a lead compound according to its potent inhibitory activity, ideal ClogP value and better water solubility.

BBI608 derivative as well as preparation and application thereof

The invention belongs to the technical field of medicines, and relates to a BBI608 derivative and application of the BBI608 derivative in an anti-tumor medicine. The structures of the derivative and apharmacologically acceptable salt are as follows: as shown in the specification, wherein X, R1, R2 and R3 are as described in claims and the specification. The derivative and the pharmacologically acceptable salt can be used for preparing the anti-tumor medicine, particularly a medicine for treating the stomach cancer (including gastric esophageal cancer) and the pancreatic cancer. An HepG2 cellactivity research finds that the cell inhibition activities of most compounds are obviously higher than that of the anti-tumor medicine BBI608.(Refer to Specification).

TREATMENT OF CANCERS RELATED TO CHRONICALLY ACTIVE RAS

The present invention discloses that naphthofuranquinones and dihydroxynaphthofurans, and derivatives thereof, such as a compound of formula I or II, are effective in deactivating chronically active Ras. The present invention also discloses a method of treating or preventing cancer comprising steps of: 1) identifying a patient suffering from or susceptible to a cancer related to chronically active Ras; and 2) administering a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further discloses a method of treating or preventing cancer comprising steps of: 1) identifying a patient suffering from or susceptible to a cancer related to a K-Ras mutation; and 2) administering a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof.

Method for synthesizing coumarone naphthoquinone derivative

The invention discloses a method for synthesizing a coumarone naphthoquinone derivative. The coumarone naphthoquinone derivative is prepared by taking a compound shown in the description as a raw material through an oxidation reaction in a solvent in the action of monopersulfate ions and bromide ions. In the compound, one or two of R1, R2 and R3 are H atoms, and the other substituent groups are C1-C6 alkyl chains. The method is friendly in environment, less in experimental process, simple in preparation, high in yield, good in selectivity, and high in application value.

NOVEL STAT3 PATHWAY INHIBITOR AND CANCER STEM CELL INHIBITOR

PROBLEM TO BE SOLVED: To provide novel Stat3 pathway inhibitors, and to provide cancer stem cell inhibitors. SOLUTION: The present invention relates to: a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; met

NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES

The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.